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A B S T R A C T
Bioengineered tissues have become increasingly more sophisticated owing to recent advancements in the ﬁelds of biomaterials, microfabrication, microﬂuidics,
genetic engineering, and stem cell and developmental biology. In the coming years, the ability to engineer artiﬁcial constructs that accurately mimic the compo-
sitional, architectural, and functional properties of human tissues, will profoundly impact the therapeutic and diagnostic aspects of the healthcare industry. In this
regard, bioengineered cardiac tissues are of particular importance due to the extremely limited ability of the myocardium to self-regenerate, as well as the remarkably
high mortality associated with cardiovascular diseases worldwide. As novel microphysiological systems make the transition from bench to bedside, their im-
plementation in high throughput drug screening, personalized diagnostics, disease modeling, and targeted therapy validation will bring forth a paradigm shift in the
clinical management of cardiovascular diseases. Here, we will review the current state of the art in experimental in vitro platforms for next generation diagnostics and
therapy validation. We will describe recent advancements in the development of smart biomaterials, biofabrication techniques, and stem cell engineering, aimed at
recapitulating cardiovascular function at the tissue- and organ levels. In addition, integrative and multidisciplinary approaches to engineer biomimetic cardiovas-
cular constructs with unprecedented human and clinical relevance will be discussed. We will comment on the implementation of these platforms in high throughput
drug screening, in vitro disease modeling and therapy validation. Lastly, future perspectives will be provided on how these biomimetic platforms will aid in the
transition towards patient centered diagnostics, and the development of personalized targeted therapeutics.
1. Introduction
Cardiovascular diseases (CVDs) constitute the number one cause of
mortality worldwide, accounting for approximately 31% of all reported
deaths in 2015 [1]. In the US alone, annual direct medical costs asso-
ciated with CVDs are estimated to rise to more than USD $818 billion
by 2030, while costs associated with loss of productivity could exceed
USD $275 billion [2]. Despite signiﬁcant scientiﬁc and technological
advancements in the engineering of biomedical devices and surgical
solutions for the treatment of CVDs, the development of new ther-
apeutic strategies has been hindered by the lack of appropriate models
for high-throughput drug screening and treatment validation. Although
preclinical drug screening is almost universally carried out in vivo using
murine models, cardiovascular pathophysiology and drug response in
humans are often radically diﬀerent [3]. This in turn has led to rela-
tively high failure rates during clinical trials, raising the overall cost of
drug development and increasing the risk of unforeseen side eﬀects. For
instance, a number of Food and Drug Administration (FDA) approved
drugs for the treatment of CVDs, and even for other pathologies such as
diabetes and cancer, have been found to exert cardiotoxic eﬀects and
have thus been withdrawn from the market [4,5]. In addition, the high
costs and ethical concerns associated with the use of live animals have
brought forth the need to develop more accurate in vitro models, which
could better recapitulate cardiovascular pathophysiology and pharma-
cological responses in humans.
Conventional in vitro studies are traditionally carried out using re-
latively cheap and simple two-dimensional (2D) cultures, based on
primary cells isolated from diﬀerent animal species. More recently, cells
derived from cardiac progenitor cells (CPCs) [6], human embryonic
stem cells (ESCs) [7,8], and human induced pluripotent stem cells
(iPSCs) [9,10] have been used as pharmacological models for the eva-
luation of various cardioactive drugs. Furthermore, recent advance-
ments in genome-editing technologies have allowed the engineering of
pathological cell types for in vitro disease modeling [11]. The remark-
able ability to generate patient- and disease-speciﬁc cardiovascular
phenotypes holds great potential for the development of high-
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T
throughput drug screening platforms and personalized medicine
[12,13]. However, 2D models fail to reproduce critical phenotypic
characteristics of cardiovascular tissues such as their structural and
compositional features, as well as relevant cell–cell and cell–ex-
tracellular matrix (ECM) interactions [14]. More recently, three-di-
mensional (3D) approaches such as cardiosphere-derived cells and cell
sheets have been used to better mimic the spatial arrangements in
which cells grow in the native tissues [15,16]. These 3D systems allow
cells to actively interact with each other and the ECM in relevant spatial
arrangements, which provides biochemical and biophysical stimuli that
heavily inﬂuence cell fate. However, despite their enhanced physiolo-
gical relevance, conventional 3D cultures still lack many of the archi-
tectural [17], mechanical [18] and electroconductive [19] features of
cardiovascular tissues [20]. This in turn greatly limits their potential to
evaluate the safety and eﬃcacy of new drug candidates, since they are
not representative of the elaborate crosstalk between diﬀerent cell
types, the ECM, and the cardiovascular microenvironments.
In recent years, remarkable advancements in biomaterials science
and the development of powerful biofabrication techniques, have en-
abled the engineering of artiﬁcial human tissues that possess an un-
precedented level of physiological relevance [21–23]. Tissue en-
gineering (TE) has enabled the development of custom biomimetic
tissues, which have served as models for a plethora of applications in
pharmaceutics [24–26], regenerative medicine [27,28], diagnostics
[29], as well as fundamental research to elucidate the mechanisms that
underlie disease onset and progression [4,30,31]. Moreover, the com-
bination of TE with microfabrication techniques and microﬂuidics have
enabled the development of microphysiological systems, also termed
organs-on-chips, which can serve as systemic models of human phy-
siology and disease [32,33]. Organs-on-chips platforms oﬀer the unique
ability to host bioengineered 3D constructs in a controlled micro-
environment, while allowing the delivery of mechanical and electro-
physiological stimuli [34]. This is particularly important, since cardi-
ovascular tissues are comprised of a multitude of cell types (e.g.,
cardiomyocytes (CMs), cardiac ﬁbroblasts, endothelial cells, Purkinje
cells, etc.) arranged in an anisotropic and hierarchical organization
[32]. Furthermore, the intrinsic control system that regulates the con-
tractile function of the myocardium can respond to both external and
systemic cues, while its complex architecture is supported by a 3D
framework of various ECM proteins [35]. Therefore, the remarkable
versatility of microphysiological systems is optimal for the engineering
of in vitro models that mimic the complex structure, composition, het-
erocellularity, dynamism, and highly regulated function of cardiovas-
cular tissues (Fig. 1).
The sustained and rapid progress in the ﬁelds of TE and micro-
physiological systems has led to the development of artiﬁcial tissues
that can be used as platforms to assess drug eﬃcacy and safety before
pre-clinical assessment. Moreover, the classic paradigm of engineering
replacement tissues that could be used as grafts for therapeutic appli-
cations is rapidly evolving towards the development of sophisticated
biomimetic systems for in vitro high-throughput screening. Here, we
will review recent advancements in the development of bioengineered
in vitro models of cardiovascular tissues (i.e., blood vessels, cardiac
valves, and myocardial tissue), with an emphasis on high-throughput
drug screening and therapeutic validation. We will start with an over-
view of the diﬀerent types of smart and multifunctional biomaterials
Fig. 1. Bioengineered in vitro models of cardiovascular function and disease. Tissue engineered constructs oﬀer several advantages over conventional 2D
cultures such as enhanced physiological relevance, establishment of cell-cell and cell-ECM interactions, delivery of physicochemical cues, biomimetic micro-
architecture, and 3D gradients of stiﬀness, nutrients, biochemical factors, oxygen, etc. In the context of cardiovascular studies, the incorporation of bioengineered
tissues into microﬂuidic-based platforms allows the recapitulation and precise control over critical physiological parameters such as ﬂow, and electrical and me-
chanical stimuli. Furthermore, the generation of disease- and even patient-speciﬁc phenotypes through stem cell technology has enabled the development of highly
representative models of cardiovascular diseases. These sophisticated in vitro platforms have emerged as powerful tools for several diagnostic (biomarker discovery
and validation), and therapeutic (target identiﬁcation and validation) applications, as well as high-throughput drug safety and eﬃcacy testing.
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that have been developed to support the growth and function of car-
diovascular phenotypes in vitro. We will then discuss modern biofabri-
cation methods that have enabled the manufacture of artiﬁcial cardi-
ovascular tissue constructs with biomimetic microarchitectures and
enhanced functionality. We will also review state of the art organ-on-a-
chip models of cardiovascular function, which have emerged as testing
platforms for drug and device testing, disease modeling, and precision
medicine. Lastly, we will provide an outlook and future perspectives,
and comment on the most signiﬁcant technological and scientiﬁc
challenges that remain.
2. Biomimetic design of biomaterials for cardiovascular TE
Although some strategies for scaﬀold-free fabrication of cardiovas-
cular tissues have been reported [36–39], the development of bioen-
gineered cardiovascular constructs often requires biomaterials with
deﬁned physicochemical properties. This is mainly because the tissues
that comprise the cardiovascular system possess several unique and
diverse properties that determine their functionality (Fig. 2a). For in-
stance, the myocardium exhibits an anisotropic contractile structure,
where cells are aligned to provide increased mechanical support and
propagate electrical conductivity along the axis, parallel to the muscle
ﬁbers (Fig. 2b) [40,41]. On the other hand, adult healthy blood vessels
are multi-layered structures of varying thickness and mechanical
properties, which are comprised of elastic muscle ﬁbers in character-
istic arrangements that withstand physiologic burst pressures (Fig. 2c)
[42]. Lastly, cardiac valves possess distinct structural and functional
features, owing to stratiﬁed ECM layers that confer distinct properties
to the leaﬂets and supporting structures that undergo constant shear
stress (Fig. 2d) [42]. Therefore, biomaterials used for cardiovascular TE
should provide a biocompatible 3D framework with electrical, me-
chanical, compositional, biological, and microarchitectural features
that mimic the complexity of the native tissues.
Many research strategies have focused on the development of 3D
hydrogel scaﬀolds for cardiovascular TE using a variety of natural and/
or synthetic polymers. In contrast to naturally-derived polymers,
Fig. 2. Biomimetic design criteria for the development of scaﬀolds for cardiovascular tissue engineering. a) Schematic of a sagittal plane of the human heart
showing the three main tissues that comprise the cardiovascular system. b) Biomaterials used to develop myocardial tissues should provide a highly biocompatible
and electroconductive matrix that supports CM function. The panel shows a representative F-actin (green)/DAPI (blue) ﬂuorescent image of CMs growing on a
biologically inspired interwoven scaﬀold. The scaﬀold was comprised of aligned conductive nanoﬁber yarns, synthesized from PCL, silk ﬁbroin, and CNTs (Adapted
from Ref. [85]). c) Biomaterials used to develop TEBVs should provide adequate burst pressure and mechanical compliance, while also allowing the attachment and
proliferation of endothelial cells. The panel shows the histological assessment of endothelial cells growing on a tubular scaﬀold. The scaﬀold was comprised of
electrospun poly (L-lactide) microﬁbers (Adapted from Ref. [86]). d) Biomaterials used to develop TEHVs should be able to withstand high trans-valvular pressures
while also maintaining low ﬂexural stiﬀness. The panel shows four types of cardiac valve scaﬀolds synthesized through double component deposition (DCD) of poly
(ester urethane) urea (PEUU) microﬁbers (Adapted from Ref. [87]).
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synthetic biomaterials often allow greater control over physical prop-
erties such as mechanical stiﬀness, degradation rate, and porosity
[43,44]. More recently, smart synthetic biomaterials with enhanced
functionality such as self-assembly, self-healing, thermo-responsive-
ness, and pH-responsiveness have also been developed for TE applica-
tions [45–48]. Some examples of synthetic biomaterials that have been
extensively used for the engineering of cardiovascular constructs in-
clude poly (ethylene glycol) (PEG) [49], poly (ε-caprolactone) (PCL)
[50], poly (L-lactic acid) (PLA) [51], poly (glycolic acid) (PGA) [52],
and biodegradable polyurethanes (PUs) [53]. On the other hand, col-
lagen, gelatin, ﬁbrin, and alginate represent some of the most widely
used naturally-derived biomaterials for cardiovascular TE [54–57]. In
general, although natural polymers are known to possess high bioac-
tivity and biocompatibility, they often lack mechanical stiﬀness and
require the addition of other components for enhanced structural sta-
bility. In addition, one of the key advantages of natural polymers over
synthetic materials is the presence of intrinsic peptide sequences, which
can promote cell adhesion and proliferation in vitro [58]. However,
although synthetic and even some naturally-derived polymers do not
exhibit intrinsic cell supporting capabilities, they can be readily mod-
iﬁed through the incorporation of bioactive peptides such as RGD, CAG,
REDV, and YIGSR [59,60]. The diﬀerent types of naturally-derived and
synthetic-based biomaterials used in the development of tissue en-
gineered myocardium [61–63], cardiac valves [64–67], and blood
vessels [68–72] have been extensively reviewed in the literature and
will not be discussed here.
Despite the wide variety of biomaterials currently reported in the
literature, there is still a need for more sophisticated alternatives that
can enhance the physiological relevance of bioengineered constructs.
Thus, the development of new biomaterials for cardiovascular TE
should incorporate biomimetic design criteria, based on the speciﬁc
requirements of the diﬀerent types of tissues that comprise the cardi-
ovascular system (Fig. 2). For instance, biomaterials used to develop
bioengineered myocardial constructs should provide a substrate that
promotes the electromechanical coupling of CMs. This is mainly be-
cause the contractile function of the heart is powered by the synergistic
motion of CMs, which in turn is triggered by electrical signals that are
propagated across the myocardium [73]. In addition, previous studies
have shown that electrical stimuli can trigger diﬀerent cellular re-
sponses such as increased cardiomyogenesis of embryonic stem cells
and maintenance of the CM phenotype in vitro [74]. Despite the re-
markable biocompatibility and versatility of hydrogel-based scaﬀolds,
the insulating nature of polymeric hydrogels limits their application for
the propagation of electroactive phenotypes such as CMs. To address
this limitation, previous groups have explored the incorporation of
conductive nanomaterials such as gold, graphene oxide (GO), and re-
duced graphene oxide (rGO)nanoparticles, carbon nanotubes (CNTs),
and conductive polymers such as polyaniline (PANi), and polypyrrole
(PPy) into polymer-based hydrogels (Fig. 2b) [75–80]. These electro-
conductive hydrogels (ECHs) have been shown to promote cell-cell
interactions, and the synchronous contraction of CMs in vitro [81,82].
However, they are often hindered by several limitations, such as cyto-
toxic responses triggered by the addition of conductive components to
the polymeric network [83]. To address this, our group recently re-
ported a novel method for the development of highly biocompatible
ECHs based on the incorporation of a choline-based bio-ionic liquid
(Bio-IL) into diﬀerent polymers such as gelatin methacryloyl (GelMA)
and poly (ethylene glycol) diacrylate (PEGDA) [84]. This approach
oﬀered several technical advantages over conventional approaches,
such as high electrical conductivity and biocompatibility, as well as
tunable mechanical and microstructural properties. Similar to this ap-
proach, future strategies should also be aimed toward the development
of highly biocompatible biomaterials that can support the phenotype
and electromechanical function of CMs in vitro. This in turn will lead to
bioengineered myocardial tissues with synchronous and strong con-
tractility that can not only be used as functional grafts for therapy, but
also as models for in vitro research.
Another type of cardiovascular tissue with high clinical signiﬁcance
is blood vessels. Native vessels are comprised of multiple layers of
smooth muscle cells that provide biomechanical support to withstand
high cyclic pressures. In addition, the ECM of these tissues is rich in
elastin and collagen ﬁbers, which are arranged circularly around the
vessel. Due to these characteristic properties, native blood vessels are
highly elastic tissues with the ability to extend and retract against the
pressures of blood ﬂow, while also maintaining mechanical integrity.
Therefore, the design of tissue engineered blood vessels (TEBVs) should
incorporate biomaterials that provide adequate burst pressure, fatigue-
resistance, and mechanical compliance [88–91]. In addition, these
biomaterials should also be able to support endothelial cell attachment
and proliferation for the proper colonization of the scaﬀold (Fig. 2c).
Several groups have reported diﬀerent functionalization strategies via
the use of coatings and chemical and protein modiﬁcations to promote
the endothelialization of the scaﬀold [59,71,72,92]. For instance, dif-
ferent molecules such as fucoidan, heparin, chondroitin sulfate, hya-
luronic acid (HA), as well as antioxidant compounds and ECM proteins
including ﬁbronectin, laminin, and collagen have been used to improve
cell-material interactions to promote endothelialization [93]. These
studies have demonstrated that surface modiﬁcation often leads to in-
creased endothelial cell attachment and proliferation, as well as over-
expression of endothelial markers such as smooth muscle myosin heavy
chain (SM-MHC) [94]. Therefore, future strategies should aim towards
the development of highly biocompatible elastomeric materials that
promote endothelial cell inﬁltration and ECM deposition, while also
minimizing negative responses at the blood–material interface.
Heart valves are structures that mechanically control the unidirec-
tional blood ﬂow in the heart through the opening and closing of its
leaﬂets. Engineering heart valve constructs remains highly challenging
due to the complex geometry of their native structures, their remark-
able ability to withstand high trans-valvular pressures, and their low
ﬂexural stiﬀness [95]. In addition, valve leaﬂets possess an intricate
ECM that is comprised of three distinct layers comprised mainly of
collagen ﬁbers, proteoglycans, and elastin [95,96]. Biomaterials used to
develop tissue engineered heart valves (TEHVs) should exhibit a ﬁne
balance of stiﬀness and elasticity to mimic the mechanical property of
the native tissues [97]. Conventional approaches for the fabrication of
TEHVs are based on the use of decellularized allografts from donor
heart valves, or xenografts from animal-derived small intestine sub-
mucosa [98]. More recently, synthetic biodegradable elastomers have
emerged as attractive alternatives to allografts due to their high me-
chanical compliance, as well as their controllable chemical structure
and degradability (Fig. 2d) [67]. Furthermore, current strategies for the
development of TEHVs have shifted from the use of inert substrates
towards bioactive materials that can instruct cell behavior in vitro and
modulate tissue integration in vivo [66]. However, due to their complex
biomechanical properties, the accurate recapitulation of the biological
features of cardiac valves with a single biomaterial remains highly
challenging. Because of this, composite scaﬀolds based on cell sup-
portive materials reinforced with biocompatible elastomers, and in-
corporated with bioactive proteins/peptides/polysaccharides could be
more suitable for the development of TEHVs [67].
Despite all the signiﬁcant advancements described above, the use of
biomaterials alone is not enough to develop biomimetic constructs that
can mimic the complex microarchitecture and functionality of the na-
tive tissues. As a result, a variety of biofabrication techniques have been
developed, which allow the accurate reproduction of native physiolo-
gical structures at the micro- and nano-scale.
3. Biofabrication of physiologically relevant cardiovascular
constructs
Biofabrication refers to the combination of cells, biomaterials, and
bioactive factors with advanced fabrication techniques to generate
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functional tissue constructs, with a level of complexity exceeding
simple 2D or 3D cultures. Current fabrication techniques enable precise
control over the spatial arrangement of cells and/or materials to ac-
curately mimic the microstructural architecture and diverse composi-
tion of native tissues. Artiﬁcial tissues constructed from currently
available biomaterials and cell types can be used for a myriad of ap-
plications, including platforms to study healthy and diseased tissue
microenvironments [99,100], regenerative scaﬀolds [101], and drug
screening [102]. In the context of cardiovascular tissues, biofabrication
can be used to control the alignment of CMs to recapitulate cardiac
anisotropy, and to introduce vascularization, a feature that is essential
to cell survival in large cell-laden constructs. In this section, we will
focus on advanced biofabrication techniques to manufacture constructs
with a degree of complexity that speciﬁcally resembles native cardio-
vascular tissues.
3.1. Fiber-based methods
Fiber fabrication techniques, such as microﬂuidic spinning and
electrospinning, have the potential to generate ﬁbrous structures with
highly tunable properties, including ﬁber size, mechanical stiﬀness and
elasticity, topography, porosity, and composition [103–116]. Micro-
ﬂuidic spinning is the process of ﬂowing a liquid precursor or pre-
polymer solution within a microchannel, followed by rapid poly-
merization or crosslinking to yield a continuous solid ﬁber.
Polymerization can occur within the channel, using co-axial ﬂow sys-
tems, or at the exit of the channel, as is accomplished in wet-spinning.
Examples of materials used for microﬂuidic spinning of ﬁbers for TE
include poly (lactic-co-glycolic) acid (PLGA) [105,107], alginate
[106,108,114–116], gelatin/GelMA [109,114], PEGDA [117], collagen
[115,116], and ﬁbrin [115]. The main beneﬁt of microﬂuidic ﬁber
spinning is that it allows the direct encapsulation of cells within the
ﬁbrous structures (Fig. 3a) [118]. In addition, multiple cell types and/
or materials can be apposed together in a single or adjacent ﬁber to
fabricate tissue-like structures with diverse cellular, chemical, and
mechanical composition [110,114,119]. In the context of cardiac TE,
ﬁbrous structures can be generated to mimic cardiomuscular ﬁbers or
vasculature structures found in the native heart. For example, core-shell
Fig. 3. Biofabrication strategies to develop physiologically relevant cardiovascular tissue constructs. a) Microﬂuidic spinning enables direct encapsulation of
cells in a hydrogel ﬁber. Various types of tissues can be matured in the ﬁbrous constructs (reproduced from Ref. [118]). b) Mature blood vessel lumens can be
generated by encapsulation of HUVECs in a type-I collagen ﬁber (reproduced from Ref. [115]). c) Electrospinning onto a cylindrical rotating mandrel can be used to
generate highly aligned ﬁbers. d) ECM-based scaﬀolds can be formed by ﬁrst growing ﬁbroblasts on the mats followed by decellularization, which leaves behind a
highly proteinaceous matrix of ﬁbronectin and collagen. e) This coating method leads to cellular alignment and maintenance of the cardiac phenotype (reproduced
from Ref. [123]). f) Patterning methods, such as micromolding, can be used to align cardiac cells and measure their contractile activity in vitro. g) Combined with
microfabrication of electrical units, this platform can measure changes in cardiac contractility in response to drugs (adapted from Ref. [124]). h) A similar method
can be used to form high aspect ratio PDMS pillars. i) These pillars direct organization of cardiac cells around the PDMS pillars to generate aligned cardiac constructs
(adapted from Ref. [125]). j) Bioprinting techniques can be used to generate endothelialized tissue constructs that mimic the highly vascularized myocardium. k)
Perfusion of cell culture media in a custom-made bioreactor maintains cell viability and activity for long periods of time. l) When drugs are perfused through the
bioreactor, the tissue responds in a dose-dependent manner (reproduced from Ref. [99]). m) The use of support baths for bioprinting provides opportunities to print
complex hydrogel structures. n) An embryonic chick heart was printed with this method, using an alginate hydrogel (reproduced from Ref. [126]).
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ﬁbers laden with endothelial cells were fabricated using a specialized
dual co-axial microﬂuidic chip [115]. This dual co-axial chip was fab-
ricated by inserting a series of round pulled glass capillaries into rec-
tangular glass tubes, which were housed in plastic chambers connected
to the sheath inlets. A mixture of cells and ECM proteins was ﬂowed
through the core capillaries, and subsequently contained as a solution
of sodium alginate in the shell was crosslinked with aqueous calcium
chloride [115]. Using this method, encapsulation of human umbilical
vein endothelial cells (HUVECs) in a type-I collagen hydrogel ﬁber led
to the formation of a monolayer along the inner diameter of the ﬁber
(Fig. 3b). After cell maturation, the calcium-alginate shell could be
selectively removed with alginate lyase. This type of structure could
ultimately lead to the formation of a mature lumen. In the same study,
primary rat CMs were encapsulated in a type-I collagen/ﬁbrin hybrid
hydrogel ﬁber. By day 3 of culture, spontaneous contraction of the
entire ﬁber at a frequency of 0.5–1 Hz was observed [115]. Despite the
diversity in material and cellular composition, achievable with micro-
ﬂuidic ﬁber fabrication technology, the extruded ﬁbers are discrete and
lack secondary structure. Therefore, in many cases post-fabrication
assembly of ﬁbers, such as weaving [119,120], braiding or crocheting
[119], or knitting [121] is required to generate a structure that mimics
that of native tissues. In addition, cellular activity and function, such as
CM contraction, is highly dependent on matrix stiﬀness [122]. Thus,
post-processing of softer, compliant materials might be impractical for
constructs that lack structural integrity.
Electrospinning is another technique that is used to rapidly fabricate
mats of ﬁne ﬁbers, usually on micro- or nano-meter scales'. This ap-
proach involves the application of a high voltage to a liquid solution of
a polymer, causing the formation of a Taylor cone and rapid spinning of
ﬁne ﬁbers. Layers of the ﬁbers pack together during the spinning pro-
cess to form a thin, highly porous mat. A variety of polymers are
compatible with this technique, but general requirements for the fab-
rication are a suitable viscosity of the liquid polymer solution and rapid
evaporation of the solvent during spinning [127]. Some examples of
polymers that are commonly used in electrospinning for TE applications
include PCL [113,128–130], gelatin/GelMA [112,131], PLA [104], poly
(glycerol sebacate) PGS [129], and PLGA [132]. However, it is diﬃcult
to encapsulate cells into scaﬀolds using this technology, and thus it is
generally used for 2D cell studies, in which cells are seeded directly on
top of the ﬁbrous mats. Highly aligned ﬁbers can be spun using a dy-
namic electrospinning apparatus, in which the ﬁbers are spun onto a
rotating mandrel. The alignment is controlled by increasing the rota-
tional velocity of the mandrel [111,133]. This technique was utilized by
Suhaeri et al. for the design of a platform for cardiomyoblast diﬀer-
entiation and CM maturation [123]. Their approach consisted of elec-
trospinning highly aligned poly (L-lactide-co-caprolactone) (PLCL) ﬁ-
bers (Fig. 3c) and seeding the ﬁbrous mats with ﬁbroblasts.
Decellularization of the mat left behind ﬁbroblast-derived ECM, pro-
viding a naturally-derived proteinaceous matrix containing ﬁbronectin
and collagen type I (Fig. 3d). This ECM-containing matrix supported
diﬀerentiation of H9c2 cardiomyoblast cells, as well as phenotype
preservation of neonatal rat CMs more eﬀectively than ﬁbronectin-
coated ﬁbers (Fig. 3e). Despite the ease of fabrication and the variety of
materials compatible with electrospinning, the harsh conditions of the
process and the nanoscale dimensions of the ﬁbers make it diﬃcult to
encapsulate cells in the ﬁbers for cardiovascular TE applications. An
excellent review outlining the beneﬁts and pitfalls of microﬂuidic
spinning and electrospinning technologies for TE applications is avail-
able [127].
3.2. Micropatterning
The native myocardium is hierarchically organized into bundles of
highly vascularized and aligned cardiac muscle ﬁbers, providing the
tissue with directionally dependent properties that dictate its perfor-
mance [134]. In order to appropriately recapitulate the anisotropic
nature of the tissue in vitro, it is often necessary to present topo-
graphical cues that will ultimately mediate complex cellular organiza-
tion [135]. Common methods to generate these cues include photo-
masking [125,136–139], microcontact printing [140–142], and
micromolding [141,143,144]. These strategies are generally used to
promote alignment of cells, seeded within or on the surface of the
structures, which enhances the expression of key cardiac markers and
improves the bulk contractile force. For example, in a recent study,
grooves were generated on the surface of alginate/ﬁbronectin hydro-
gels using a micromolding technique [141]. CMs seeded on these
structures exhibited signiﬁcantly higher alignment of sarcomeric alpha-
actinin, smooth muscle cells, and ﬁlamentous actin. In addition, the
muscular thin ﬁlms (MTFs) that were formed on the hydrogel surface
demonstrated high contractile stresses when stimulated under an elec-
tric ﬁeld. Lind et al. used a similar method to align human induced
pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) on a micro-
patterned polydimethylsiloxane (PDMS) sheet, but also added layers
beneath the patterned substrate capable of recording electrical activity
of the iPSC-CMs contracting and relaxing in real time (Fig. 3f) [124].
The extended utility of this device for high-throughput drug screening
was demonstrated by collecting readings from aligned iPSC-CMs in the
presence of various cardiac drugs. The introduction of diﬀerent drugs to
the MTFs elicited a similar response in beating properties and con-
tractile stress for iPSC-CMs, which suggested that this platform could be
used to predict drug eﬀects in humans for pre-clinical validation
(Fig. 3g). Micromolding and microcontact printing techniques are re-
markably useful to produce aligned cellular constructs, but these stra-
tegies are generally considered as 2D and are limited in their ability to
truly recapitulate the 3D nature of native tissues. In this regard, one
group used micromolding to form high aspect ratio pillars of PDMS
elastomer, followed by seeding a cardiac cell-laden ﬁbrin hydrogel in
the inter-pillar space (Fig. 3h) [125,145]. Using this approach, they
observed considerable organization of muscle cells around the pillars,
highly aligned sarcomeric alpha-actinin and DAPI-stained nuclei, as
well as enhanced expression of the connexin-43 junction protein
(Fig. 3i).
Photomasking is a technique compatible with photosensitive ma-
terials that can be used to produce quasi-3D structures. Currently, there
is an abundance of biomaterials compatible with photomasking, in-
cluding polymers that are formed with chemistries such as acryloyl/
methacryloyl chain-growth polymerization [146], thiol-ene click
chemistry [147], thiol-Michael addition, thiol-yne, and others [148].
The generation of biomolecule patterns usually requires modiﬁcation of
the molecule to incorporate a photosensitive functional group [149].
Some of these reactions require the addition of a photoinitiator, which
is activated in the presence of light and propagates the radical reaction.
Biocompatible photoinitiators include 2-Hydroxy-4′-(2-hydro-
xyethoxy)-2-methylpropiophenone (Irgacure 2959) [150], lithium
phenyl-2,4,6-trimethylbenzoylphosphinate (LAP) [151], Eosin Y dis-
odium salt/triethanolamine co-initiators [152], riboﬂavin/triethanola-
mine co-initiators [153], as well as other less commonly used photo-
initiators such as bis(2,4,6-trimethylbenzoyl)-phenylphosphineoxide
(Irgacure 819), 1,5-diphenyl-1,4-diyn-3-one (diynone), and cam-
phorquinone (CQ)/N,N-dimethylaminobenzoic acid ethyl ester (DMAB)
co-initiators [154]. These structures are termed “quasi-3D” because the
height of the structures is generally much smaller than the length and
width, resulting high aspect ratio hydrogels that are not truly 3D. For
example, Aubin et al. generated parallel lines of 3T3 ﬁbroblast-laden
GelMA hydrogels using a photomasking technique [139]. High degree
of cellular alignment was achieved by decreasing the line width from
200 μm to 50 μm over the course of 5 days, and as the cells spread
within the patterned lines. In a similar study, CMs and cardiac ﬁbro-
blasts were co-cultured within micropatterned GelMA constructs [155].
No signiﬁcant diﬀerences in cell alignment were observed as the width
of the constructs was decreased from 500 μm to 125 μm. However,
constructs with diameters smaller than this were not tested, and it has
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been shown that a diameter smaller than 100 μm is required to induce
alignment for cardiac cells [156]. The same methodology can be ap-
plied to create patterns of materials that inhibit cell attachment, thus
conﬁning the cells to regions of unexposed material. One example of
this technique is the patterning of photocrosslinkable chitosan onto
glass or PLL-coated polystyrene [157]. Cardiac cells cultured on these
platforms preferentially attached to the chitosan-free regions, directing
their alignment along thin (< 100 μm) lanes. Photopatterning can also
be used to create biomimetic gradients in stiﬀness [158] and/or bio-
molecule concentration [159]. Gradients in stiﬀness drive durotaxis,
the migration of cells across a stiﬀness gradient, whereas molecule
gradients drive chemotaxis, cell migration over a concentration gra-
dient. In vitro studies of durotaxis can elucidate mechanisms such as
diﬀerentiation and muscle tissue innervation [160], both of which are
important parameters for understanding CVDs [161,162]. For example,
Tse et al. formed a polyacrylamide hydrogel with a stiﬀness gradient by
photocrosslinking the hydrogel precursor through a mask with a gra-
dient in transparency. Mesenchymal stem cells (MSCs) cultured on the
hydrogel with a stiﬀness gradient of 1.06 ± 0.1 kPa/mm, similar to
gradients found in both the diseased and healthy myocardium, were
shown to durotax up the gradient (i.e., towards the stiﬀer regions of the
gel), and then diﬀerentiated into a more contractile muscle-like phe-
notype [163]. Generally, photopatterning techniques enable precise
control over the spatiotemporal arrangement of biomaterials, ex-
panding their utility to serve as platforms for generating tissue-like
patterns [148].
3.3. 3D bioprinting
Although the fabrication methods discussed in the previous sections
have proven useful in recapitulating some complexities of native car-
diovascular tissues, several challenges remain that limit their ability to
generate large-scale, physiologically relevant tissues in vitro. 3D bio-
printing is one of the most advanced biofabrication techniques avail-
able to generate complex biomimetic structures. Several types of bio-
printing techniques exist, such as stereolithography [164,165], inkjet
[166], extrusion [167], two-photon polymerization [168], and laser-
induced forward transfer [169]. However, there are several design
criteria that must be considered to determine the best printing method
for a speciﬁc application. Previous reviews provide a complete over-
view of the advantages and disadvantages of the various forms of bio-
printing and bioinks [170,171]. The ability for autonomous multi-scale
layer-by-layer processing via bioprinting allows the fabrication of
constructs with considerably larger size and precision in all directions.
In addition, bioprinting techniques are usually amenable to the use of
multiple materials and thus, multi-cell deposition in a single print. This
in turn allows to more accurately replicate the diverse cellular and
compositional demographic of native tissues. One example of this is the
incorporation of vascular networks into large constructs, which enables
fabrication of larger, vascularized tissue constructs that mimic blood
perfusion in native tissues. For example, Lee et al. employed a bio-
printing technique to generate a microvascular network comprised of
large (∼1mm diameter) pre-formed synthetic vessels [172]. Their
approach involved printing large vascular channels in a parallel ar-
rangement and culturing endothelial cells in a ﬁbrin gel between the
channels. Perfusion of endothelial cell growth media through the large
channels led to spontaneous angiogenic sprouting from the large ves-
sels, and microcapillary formation between the larger channels. In ad-
dition, the diﬀusion of 10 kDa dextran through the vascular system
revealed that constructs with capillaries showed faster diﬀusion rates
compared to constructs without the microcapillary network. In another
study, a microﬂuidic approach was used to directly print perfusable
vascular conduits in a single continuous printing step [173]. Constructs
with perfusable endothelialized channels such as the ones developed in
this work can also be used to study the pharmacokinetics of drugs in
large cardiovascular constructs.
Bioprinting has yet to realize its full potential in generating func-
tional cardiovascular constructs; however, some studies have shown
promising results in fabricating cardiac-like tissues in vitro. For in-
stance, an endothelialized myocardium was constructed in vitro with a
microﬂuidic bioprinting strategy employed by Zhang et al. [102]. They
fabricated a platform for vascularization that could later be seeded with
CMs, by ﬁrst printing ﬁlaments laden with endothelial cells -mimicking
the highly vascularized myocardium (Fig. 3j). Endothelial cells mi-
grated to the periphery of the printed ﬁlaments and CMs aligned par-
allel to the extruded ﬁlaments, which were arranged in a layered lattice
pattern. Long-term viability and function were preserved by main-
taining the tissue-like structure in the center of a custom-made perfu-
sion bioreactor (Fig. 3k). They demonstrated the utility of their plat-
form as a basic model for drug screening with a common anti-cancer
model drug, doxorubicin. The cardiac tissues responded to the perfused
solution of doxorubicin in a dose-dependent manner, exhibiting en-
hanced reduction in beating rate concomitant with an increase in drug
concentration (Fig. 3l). Although these models had structural properties
and cell composition similar to the native myocardium, there are sev-
eral obstacles that remain. In general, one of the main issues associated
with this and other bioprinting methodologies is the use of printing
patterns in the shape of stacked rectilinear lattices [174]. Although this
printing pattern is often chosen to improve the bulk structural integrity
of the printed constructs, this grid-like order does not exist in native
tissues [126]. To improve upon the extensive work that has been per-
formed in the ﬁeld of bioprinting, eﬀorts must be made to support
printing of complex 3D structures that more closely resemble native
tissue architecture. One major setback is that softer biomaterials, which
would allow for better spreading, fusion, and diﬀerentiation of cells in
their 3D structures, are not self-supporting. Because of this, previous
groups have explored approaches to stabilize printed structures through
the addition of rheology modiﬁers such as cellulose nanoﬁbers [175],
or by printing support structures coincidently with a soft hydrogel. For
instance, Kang et al. developed an integrated tissue-organ printer
(ITOP) that extruded stiﬀ PCL ﬁlaments alongside soft cell-laden hy-
drogels to provide structural support to the large 3D matrices [176].
Although the authors suggested that the PCL supports would degrade as
the tissue grows, the degradation rate of PCL is particularly slow [177].
Since tissue morphogenesis is highly dependent upon substrate stiﬀness
[178], the presence of PCL in soft tissues might elicit unexpected cel-
lular responses. More recently, other groups have investigated the use
of support baths as a new methodology for printing complex structures
(Fig. 3m) [126,179,180]. These methods help circumvent the limita-
tions associated with the use of softer biomaterials for 3D printing of
hydrogels [171]. For instance, Hinton et al. demonstrated the ability to
print soft tissue structures such as an embryonic chick heart (Fig. 3n)
and a human brain scaled to 3 cm in length, by directly extruding al-
ginate into a support bath of gelatin microparticles and calcium
chloride [126]. Since gelatin melts at physiological temperatures, the
printed structure could easily be released after incubation at 37 °C.
Novel printing strategies such as this have great potential to expand the
possibilities of using 3D printing for cardiovascular applications.
Biofabrication strategies have shown tremendous promise in re-
capitulating the native microarchitecture of human tissues, using stra-
tegies that involve a calculated combination of cells and biomaterials.
Despite the beneﬁts of biofabrication as a method that can generate
microscale biomimetic features, the experimental implementation of
bioengineered constructs in drug screening and disease modeling still
presents some technical limitations. For instance, in vitro platforms for
pharmacological assessment require real-time monitoring of cellular
activity as external stimuli or drugs are introduced to the system.
Moreover, microtissues grown under conventional culture conditions
are not able to reproduce the dynamic heterocellular interactions that
occur in native cardiovascular microenvironments. In this regard, mi-
crophysiological on-chip models have shown great promise as platforms
for building culture systems with tissue- and organ-level functionality.
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4. Cardiovascular organ-on-a-chip platforms
Due to the complexity of the cardiovascular system, there are sev-
eral diseases associated with diﬀerent structural components of cardi-
ovascular tissues (e.g., valves, Purkinje ﬁbers, ventricles, veins, cor-
onary arteries, capillaries, etc.), as well as the various cell types that
make up these tissues (e.g., cardiac ﬁbroblasts, endothelial cells, pa-
cemaker cells, nodal cells, epicardial cells, smooth muscle cells, CMs,
etc.) (Fig. 4a). Therefore, the mechanistic investigation of CVDs, the
development of new therapeutic drugs, and microphysiological and
electrophysiological studies of cardiac function have always been
among the most active topics in biomedical research [181]. However,
due to the systemic component and the remarkable heterogeneity be-
tween the cellular and molecular mechanisms of CVDs, conventional in
vitro models do not provide an adequate level of physiological re-
levance. Furthermore, traditional in vitro approaches are not capable of
direct measurement and modulation of complex biological variables,
limiting their ability to screen important clinical parameters [182]. To
overcome these limitations, diﬀerent groups have focused on the de-
velopment of miniaturized culture platforms termed organs-on-chips
[181,183]. These microphysiological models can mimic the function of
complex cardiovascular tissues, while also allowing the measurement of
key biological responses in a high-throughput fashion. This is achieved
mainly through advanced mincroengineering technologies such as mi-
croﬂuidics, microfabrication, and microelectronics. Furthermore, these
“heart-on-a-chip” platforms not only circumvent the limitations of
conventional in vitro models, but they also enable the recapitulation of
complex phenomena such as ﬂow and electromechanical stimuli, dis-
ease physiopathology, and tissue- and organ-level responses to drugs
[184].
Heart-on-a-chip platforms have been mainly used to investigate the
spatial arrangements and functional interactions between diﬀerent
cardiac phenotypes (Fig. 4b), and for the targeted stimulation of cardiac
cells/stem cells to yield functional cardiac microtissues (Fig. 4c) [181].
In this regard, a variety of biochemical [187,189–193], mechanical
(e.g., strain and shear force) [192,194–198], physical (e.g., surface/
structural features) [190,199–203], electrical [196,204–209], optical
[210–212], as well as thermal and magnetic [213,214] stimuli have
been shown to inﬂuence the diﬀerentiation, alignment, and physiolo-
gical behavior of cardiac cells/stem cells in vitro. For instance, Marsano
et al. engineered a microphysiological model to study the mechanical
function of the myocardium. This microengineered device delivered
homogeneous uniaxial cyclic strain to cell-laden scaﬀolds, which ulti-
mately yielded mature and functional cardiac microtissues [215]. This
platform could also be used to study hypertrophic changes occurring in
cardiac tissues triggered by the combined action of mechanical and
biochemical stimulation. In another study, Ma et al. developed an in
vitro model of the myocardium through the integration of a micro-
electrode array-based biochip, laser-patterning, and microfabrication
[207]. They used this platform to analyze the diﬀerences in electrical
conductivities of diﬀerent cell types within the myocardium. Their re-
sults demonstrated that stem cell-CM bridges showed stronger and
more stable electrical signaling through gap junctions, when compared
to myocyte-ﬁbroblast contacts [207].
Apart from mechanical stimulation, electrical stimulation of cardiac
cells is one of the most important factors to accurately mimic the
contractile function of native cardiac tissues [196,204–209,216–218].
Previous groups have explored the use of electrical stimuli to modulate
the rate and duration of action potentials in CMs in vitro, which in turn
promotes the synchronous contraction of bioengineered tissue
Fig. 4. Diﬀerent biomedical applications of heart-on-a-chip platforms. a) Schematic of a human heart, showing the diﬀerent cell types contributing to structural
support, and its biochemical, mechanical, electrical and functional properties (adapted from Ref. [185]). Heart-on-a-chip platforms have emerged as versatile
platforms with several diﬀerent applications, including: b) Mechanistic studies of cardiac function. Schematic of a microphysiological device engineered via mul-
timaterial 3D printing and used for generating functional stem cell-derived laminar cardiac tissues (adapted from Ref. [186]); c) Delivery of physiological stimuli to
cells and tissues. Schematic of an integrated microﬂuidic device for mechanical stimulation, and representative ﬂuorescent images of iPSC-CMs (adapted from Refs.
[187,188]); d) In vitro disease modeling. Representative ﬂuorescent images (right) of iPSC-CMs laden elastomers with ﬁbronectin patterned lines, self-organized into
anisotropic myocardial tissues, and (left) control (WT) and BTHS iPSC-CMs (PGP1-TAZ) showing diﬀerences in the distribution and morphology of mitochondria
(adapted from Ref. [189]); and e) Design of microengineered platforms for in vitro drug safety and eﬃcacy testing, which can be used for the development of
personalized targeted therapies.
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constructs [219–222]. This is mainly because direct electrical stimu-
lation mediates the release and re-uptake of Ca2+ ions via the sarco-
plasmic reticulum, which directly inﬂuences the contractile function of
CMs. Moreover, diﬀerent studies have shown that electrical stimulation
inﬂuences the expression of cardiac markers and aﬀects cell migration
and alignment, as well as the formation of gap junctions and inter-
cellular connections [223–227]. In another study, Chen et al. designed
an on-chip microsystem that mimicked the pumping functionality of
the heart. This microﬂuidic circulatory system was comprised of on-
chip pressure sensors, four pumping units, and passive check valves to
mimic the four cardiac chambers and the heart valves in vitro [228].
This microsystem enabled the precise monitoring and control of the
circulatory pressure and the beating rate. Therefore, the engineered
heart-on-a-chip system could potentially be used for physiological
studies of blood circulation and also for the modeling of CVDs such as
bradycardia, tachycardia, and hypotension [228].
In addition to the electromechanical stimulation of bioengineered
tissues, heart-on-a-chip systems have also been used for modeling and
mechanistic studies of CVDs such as myocardial infarction, arrhythmia,
cardiomyopathy and ischemia (Fig. 4d) [229,230]. For instance, var-
ious research groups have investigated the diﬀerences in cellular or-
ganization and alignment using electrical ﬁelds for the in vitro mod-
eling of cardiac arrhythmias [223,231–233]. In a recent study, Ren
et al. used a microﬂuidic platform to develop a micropillar array-aided
platform to mimic hypoxia-induced myocardial injury [229]. Using
this system, diﬀerent apoptotic responses of myocardial cells such as
cell shrinkage, cytoskeleton disintegration, activation of caspase-3, and
decrease in mitochondrial membrane potential could be monitored.
Their results suggested that this platform could be used not only to
study cellular responses to myocardial infarction, but also for the in-
vestigation of organ/tissue disease dynamics [229]. Furthermore,
heart-on-a-chip models could play a key role in the comprehensive
screening and investigation of rare diseases that lack adequate pre-
clinical and clinical models [234]. For instance, Wang et al. developed
a heart-on-a-chip model using patient-derived and genetically en-
gineered iPSCs to study the pathophysiologic basis of the cardiomyo-
pathy of Barth syndrome (BTHS), a particularly rare mitochondrial
disorder [189]. They used this platform to show that the abnormal
contractile function of CMs in BTHS occurs due to mutations in the
Tafazzin (TAZ) gene, and to investigate potential treatment strategies
against BTHS. Taken together, these studies highlight the potential of
on-chip models to elucidate key disease mechanisms, which in turn
could aid in the identiﬁcation of novel therapeutic targets [189,235].
Microscale heart-on-a-chip platforms can be also used for screening
drugs for the treatment of CVDs, evaluating cardiotoxic side eﬀects,
and identifying multiple drug interactions (Fig. 4e) [181]. Currently,
several drugs (e.g., Clomacron, Astemizole, Fen-phen, Prenylamine,
Dexfenﬂuramine, Chlorphentermine, and Terfenadine) have been
withdrawn by the FDA due to various hepatotoxic, and cardiotoxic side
eﬀects, such as the development of fatal arrhythmias, ventricular ta-
chycardia, CVD, and cardiac ﬁbrosis [236,237]. Heart-on-a-chip plat-
forms can provide suitable, cost-eﬀective, and time-eﬃcient drug
testing during pre-clinical stages, due to their high degree of biomi-
micry and human relevance [183]. Because of these characteristics,
microphysiological platforms can be remarkably useful in the de-
termination of the safety, eﬃcacy, and side eﬀects of drugs for the
treatment of cardiovascular and other diseases. This in turn can dra-
matically reduce the costs associated with preclinical assessment, de-
velopment, production, and implementation of therapeutic drugs
[222]. In this regard, biological variables such as cell viability, ex-
pression of cardiac markers, rate and synchronicity of CM contraction,
and several other functional parameters can be evaluated to establish
optimal drug dosages and regimens [181,222]. For instance, Agarwal
et al. developed a microengineered heart-on-a-chip system to in-
vestigate the inotropic eﬀect of isoproterenol (a non-selective β-adre-
nergic agonist used for the treatment of bradycardia) on theT
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contractility of neonatal rat ventricular myocytes, using a 3D multi-
cellular culture system [238]. Using this approach, they could rapidly
and eﬀectively measure the contractile function of the cells across a
wide range of drug concentrations (i.e., from 1 nM to 100mM), which
demonstrated the capability of their system for pharmacological as-
sessment. In another study, Mathur et al. developed a cardiac micro-
physiological system to determine the toxicity of diﬀerent drugs, using
both iPSCs and native tissues [239]. This platform was able to support
the viability and functionality of iPSC-derived cardiac tissues for several
weeks. Using this approach, they evaluated the eﬀect of drugs on the
electrophysiological behavior of the cells, following the administration
of varying doses of diﬀerent drugs including Verapamil, Isoproterenol,
Metoprolol, and E-4031.
The remarkable versatility of on-chip platforms originates in part
from the ability to incorporate diﬀerent cell culture approaches de-
pending on the requirements of each experimental design. To this date,
on-chip evaluation of drugs for cardiovascular applications has been
conducted using 2D [199] and 3D cultures, bioprinted tissues
[186,240,241], single cells [242–244], as well as multicellular cultures
[230,245–247]. Table 1 shows a summary of diﬀerent types of on-chip
systems for biomedical applications, including cell/tissue stimulation,
CVD modeling, as well as drug safety and eﬃcacy testing.
5. Current outlook and future perspectives
The development of biomimetic in vitromodels of the cardiovascular
system remains particularly challenging, mainly due to the complex
dynamics of relevant physiological phenomena such as blood ﬂow,
mechanical stretching, and electrical stimulation. In recent years, the
development of advanced biomaterials with tailored physical, bio-
chemical, and biological features, as well as their integration with
modern biofabrication approaches has enabled the development of
bioengineered constructs with tissue-level complexity. Bioengineered
tissues have become increasingly more sophisticated, which has en-
hanced their therapeutic potential for the regeneration and repair of
cardiovascular tissues. However, a major opportunity also exists to
implement these biomimetic 3D models for the study of the cellular and
molecular mechanisms that drive CVD onset and progression. In addi-
tion, the integration of bioengineered tissues with perfusable micro-
ﬂuidic networks that mimic the vasculature not only allows the delivery
of nutrients and soluble biomolecules, but also contributes to the
functional maturation and interaction of diﬀerent cardiovascular
Fig. 5. Implementation of bioengineered tissues and on-chip platforms for high-throughput screening and precision medicine. a) Patient-speciﬁc cells, both
terminally mature and undiﬀerentiated progenitors, can be used as cell sources for personalized medicine applications, which include: b) Microscale biomimetic
tissue constructs for the rapid and high throughput assessment of drug safety and eﬃcacy; c) Development of organ-on-a-chip platforms for disease modeling, based
on the modulation of physiological determinants, such as abnormal ﬂow, electrical stimulation, and tissue mechanics; d) Design of organ-on-a-chip platforms to
facilitate the development of personalized therapeutic regimes that take into account the genetic make-up and the remarkable heterogeneity of each individual
patient.
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phenotypes. In the context of CVDs, on-chip platforms provide un-
paralleled technical advantages, since they enable the precise manip-
ulation of ﬂow rate and shear stress for the recapitulation of capillary,
arterial, and venous ﬂow behavior under diﬀerent pathological condi-
tions. Furthermore, microphysiological platforms allow the rapid and
reproducible measurement of relevant physiological parameters for the
high throughput evaluation of drug safety and eﬃcacy.
Drug development for CVDs remains particularly challenging since
clinical trials often involve large numbers of patients that need to be
monitored over extended periods of time, while the tolerance of these
patients to adverse side eﬀects is extremely low. These and other ob-
stacles associated with the availability of experimental models and the
high variability among individual patients have signiﬁcantly slowed
down the pace of new drug development. In this regard, on-chip plat-
forms hold great potential to narrow the gap between conventional in
vitro models and live animals used for in vivo experimentation, thus
lowering the time, resources, and ethical concerns associated with
current approaches. Despite this remarkable versatility, several tech-
nological and scientiﬁc challenges remain. Pioneering studies on on-
chip platforms have relied mainly on animal-derived cells due to their
ease of accessibility and relatively simple manipulation. However, these
cells are not representative of human physiology and exhibit marked
diﬀerences in drug response and disease mechanisms, which highlights
the need for the use of cells of human origin. Recent developments in
iPSC technologies and recombinant DNA techniques have enabled the
diﬀerentiation of functional human cardiovascular phenotypes in the
laboratory (Fig. 5a) [253,254]. Moreover, the fact that iPSCs can be
generated on a patient by patient basis is remarkably advantageous for
the development of in vitro models for personalized drug screening
(Fig. 5b) and for the understanding of patient speciﬁc fundamentals
related to CVDs (Fig. 5c). However, although research on cardiovas-
cular genetics has made signiﬁcant progress in the last decade, perso-
nalized therapeutic strategies based on the genetic makeup of in-
dividual patients are scarce (Fig. 5d) [255].
In future years, the eﬃcient translation of technological advance-
ments in the ﬁelds of device miniaturization, additive 3D manu-
facturing, and microelectronics will allow the development of fully
instrumented microphysiological systems that can be readily integrated
into cost-eﬀective and automated platforms. In addition, future devel-
opments in the ﬁelds of TE, iPSC engineering, and DNA editing will
enable the eﬃcient translation of organ- and disease complexity into
microscale tissues for personalized therapeutics and diagnostics.
However, the implementation of iPSC-based TE strategies will also re-
quire the establishment of standardized protocols for the high-
throughput evaluation of functional cardiovascular phenotypes, and the
accurate recapitulation of disease states [253]. Moreover, the devel-
opment of platforms based on the integration of healthy and diseased
tissues, as well as multi-organ experimental set ups are required to
accurately mimic cardiovascular pathophysiology. However, the in-
tegration of multiple organs-on-chips has led to new technical chal-
lenges related to organ scaling based on size and function, the devel-
opment of universal culture media, as well as the determination of the
smallest functional units that can still recapitulate drug responses in the
native organs. Despite these and other challenges, future scientiﬁc and
technological developments stemming from the collaboration between
clinicians, engineers, and industry experts will certainly facilitate the
validation and clinical translation of biomimetic in vitro models. This in
turn will lead to more eﬃcient, safe, and ethical strategies for the
widespread commercialization of biomedical devices, drugs, and per-
sonalized theranostic solutions.
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